Benefits of probiotics in Autism Spectrum Disorders : A meta-analysis of RCTs
Abstract
Using probiotics as a pharmaceutical intervention is based on the fact that dysbiosis affects many people with autism spectrum disorders (ASD). This study aimed to quantify various probiotics’ overall and individualized benefits in treating ASD. Randomized or cross-over trials comparing the efficacy of placebo or active control vs. probiotics in patients of any age diagnosed with ASD based on DSM IV/V criteria were considered under inclusion criteria. An electronic database search in PUBMED and Cochrane Library was conducted using MeSH search terms “probiotics” AND “Autism.” Mean change in the total score of clinical parameters used to assess ASD symptom severity was the primary outcome measure analyzed. All the outcome measures were estimated by calculating the Standardized Mean Difference (SMD) values and their 95% Confidence Intervals (CI), considering the different clinical parameters used to assess the change in ASD symptoms in identified clinical trials. An insignificant decrease in the total score value of primary outcome measure by -0.14 (SMD: 0.14, 95% CI:-0.45 to 0.17) in patients treated with probiotics was observed. The quantity of decrease remained insignificant in subgroup analyses also. Observed insignificant clinical benefits of probiotics in ASD patients could be due to the presence of gastrointestinal symptoms as co-morbidity. We hypothesize that intolerance to dietary components is responsible for gastrointestinal symptoms and inflammation. Perhaps probiotics are still beneficial in ASD patients without gastrointestinal symptoms, while their combination with prebiotics is effective in patients with gastrointestinal symptoms.
Keywords
Full Text:
PDFReferences
Zhou JG, Huang L, Jin SH, Xu C, Frey B, Ma H, et al. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials. ESMO Open. 2020;5:e000621.
Herrstedt J, Roila F, Warr D, Celio L, Navari RM, Hesketh PJ, et al. 2016 Updated MASCC/ESMO consensus recommendations: prevention of nausea and vomiting following high emetic risk chemotherapy. Supportive Care in Cancer. 2017;25:277-288.
Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. Journal of Clinical Oncology. 2017;35:3240-3261.
Shi Q, Li W, Li H, Le Q, Liu S, Zong S, et al. Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison. Oncotarget. 2016;7:24402-24414.
Jin Y, Jin G, Zhao J, Jiang C, Zhao L, Jiang Y, et al. Clinical Observation of Gene Polymorphism of Olanzapine or Aprepitant in Prevention of CINV. Pharmacogenomics and Personalized Medicine. 2021;14:867-875.
Fattorusso A, Di Genova L, Dell’Isola GB, Mencaroni E, Esposito S. Autism spectrum disorders and the gut microbiota. Nutrients. 2019;11:521.
Wang Y, Li N, Yang JJ, Zhao DM, Chen B, Zhang GQ, et al. Probiotics and fructo-oligosaccharide intervention modulate the microbiota-gut brain axis to improve autism spectrum reducing also the hyper-serotonergic state and the dopamine metabolism disorder. Pharmacological research. 2020;157:104784.
Li YQ, Sun YH, Liang YP, Zhou F, Yang J, Jin SL. Effect of probiotics combined with applied behavior analysis in the treatment of children with autism spectrum disorder: a prospective randomized controlled trial. Zhongguo dang dai er ke za zhi= Chinese journal of contemporary pediatrics. 2021;23:1103-1110.
Arnold LE, Luna RA, Williams K, Chan J, Parker RA, Wu Q, et al. Probiotics for gastrointestinal symptoms and quality of life in autism: a placebo-controlled pilot trial. Journal of child and adolescent psychopharmacology. 2019 ;29:659-669.
Liu YW, Liong MT, Chung YC, Huang HY, Peng WS, Cheng YF, et al. Effects of Lactobacillus plantarum PS128 on children with autism spectrum disorder in Taiwan: a randomized, double-blind, placebo-controlled trial. Nutrients. 2019;11:820.
Sanctuary MR, Kain JN, Chen SY, Kalanetra K, Lemay DG, Rose DR, et al. Pilot study of probiotic/colostrum supplementation on gut function in children with autism and gastrointestinal symptoms. PloS one. 2019;14:e0210064.
Santocchi E, Guiducci L, Prosperi M, Calderoni S, Gaggini M, Apicella F, et al. Effects of probiotic supplementation on gastrointestinal, sensory and core symptoms in autism spectrum disorders: a randomized controlled trial. Frontiers in psychiatry. 2020:944.
Kong XJ, Liu J, Liu K, Koh M, Sherman H, Liu S, et al. Probiotic and oxytocin combination therapy in patients with autism spectrum disorder: A randomized, double-blinded, placebo-controlled pilot trial. Nutrients. 2021;13:1552.
Billeci L, Callara AL, Guiducci L, Prosperi M, Morales MA, Calderoni S, et al. A randomized controlled trial into the effects of probiotics on electroencephalography in preschoolers with autism. Autism. 2022:13623613221082710.
Song W, Zhang M, Teng L, Wang Y, Zhu L. Prebiotics and probiotics for autism spectrum disorder: a systematic review and meta-analysis of controlled clinical trials. Journal of Medical Microbiology. 2022;71:001510.
Fallah MS, Shaikh MR, Neupane B, Rusiecki D, Bennett TA, Beyene J. Atypical antipsychotics for irritability in pediatric autism: a systematic review and network meta-analysis. Journal of child and adolescent psychopharmacology. 2019;29:168-180.
Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. British Medical Journal. 2011;343.
Talbott SM, Talbott JA, Stephens BJ, Oddou MP. Effect of coordinated probiotic/prebiotic/phytobiotic supplementation on microbiome balance and psychological mood state in healthy stressed adults. Functional Foods in Health and Disease. 2019;9:265-275.
Suganya K, Koo BS. Gut–Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. International Journal of Molecular Sciences. 2020;21:7551.
Oh D, Cheon KA. Alteration of gut microbiota in autism spectrum disorder: An overview. Journal of the Korean Academy of Child and Adolescent Psychiatry. 2020;31:131.
Al-Beltagi M. Autism medical comorbidities. World journal of clinical pediatrics. 2021;10:15.
Hansen L, Roager HM, Søndertoft NB, Gøbel RJ, Kristensen M, Vallès-Colomer et al. A low-gluten diet induces changes in the intestinal microbiome of healthy Danish adults. Nature communications. 2018;9:1-3.
Skott E, Yang LL, Stiernborg M, Söderström Å, Rȕegg J, Schalling M, et al. Effects of a synbiotic on symptoms, and daily functioning in attention deficit hyperactivity disorder–A double-blind randomized controlled trial. Brain, behavior, and immunity. 2020;89:9-19.
Grimaldi R, Gibson GR, Vulevic J, Giallourou N, Castro-Mejía JL, Hansen LH, et al. A prebiotic intervention study in children with autism spectrum disorders (ASDs). Microbiome. 2018;6:1-3.
Lomax A, Calder P. Prebiotics, immune function, infection and inflammation: A review of the evidence. British Journal of Nutrition. 2008;101:633-658.
Warman DJ, Jia H, Kato H. Potential roles of probiotics, resistant starch, and resistant proteins in ameliorating inflammation during aging (inflammaging). Nutrients.2022; 14:747.
Leo A, De Caro C, Mainardi P, Tallarico M, Nesci V, Marascio N, et al. Increased efficacy of combining prebiotic and postbiotic in mouse models relevant to autism and depression. Neuropharmacology. 2021;198:108782.
Parracho HM, Gibson GR, Knott F, Bosscher D, Kleerebezem M, McCartney AL. A double-blind, placebo-controlled, crossover-designed probiotic feeding study in children diagnosed with autistic spectrum disorders. International Journal of Probiotics and Prebiotics. 2010;5:69.
DOI: https://doi.org/10.15416/pcpr.v8i1.40063
Refbacks
- There are currently no refbacks.
